These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
12. Comparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE). Packer M; Califf RM; Konstam MA; Krum H; McMurray JJ; Rouleau JL; Swedberg K Circulation; 2002 Aug; 106(8):920-6. PubMed ID: 12186794 [TBL] [Abstract][Full Text] [Related]
13. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063 [TBL] [Abstract][Full Text] [Related]
14. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Candido R; Jandeleit-Dahm KA; Cao Z; Nesteroff SP; Burns WC; Twigg SM; Dilley RJ; Cooper ME; Allen TJ Circulation; 2002 Jul; 106(2):246-53. PubMed ID: 12105166 [TBL] [Abstract][Full Text] [Related]
15. Differential tissue and enzyme inhibitory effects of the vasopeptidase inhibitor omapatrilat in the rat. Kubota E; Dean RG; Hubner RA; Casley DJ; Johnston CI; Burrell LM Clin Sci (Lond); 2003 Sep; 105(3):339-45. PubMed ID: 12741953 [TBL] [Abstract][Full Text] [Related]
16. Vasopeptidase inhibition in a canine model of exercise-induced left ventricular dysfunction. Holzgrefe HH; Arthur SR; Powell JR Clin Exp Pharmacol Physiol; 2002 Aug; 29(8):696-703. PubMed ID: 12100002 [TBL] [Abstract][Full Text] [Related]
17. Omapatrilat limits infarct size and lowers the threshold for induction of myocardial preconditioning through a bradykinin receptor-mediated mechanism. Ebrahim Z; Baxter GF; Yellon DM Cardiovasc Drugs Ther; 2004 Mar; 18(2):127-34. PubMed ID: 15162074 [TBL] [Abstract][Full Text] [Related]
18. Mechanism of vasopeptidase inhibitor-induced plasma extravasation: comparison of omapatrilat and the novel neutral endopeptidase 24.11/angiotensin-converting enzyme inhibitor GW796406. Sulpizio AC; Pullen MA; Edwards RM; Louttit JB; West R; Brooks DP J Pharmacol Exp Ther; 2005 Dec; 315(3):1306-13. PubMed ID: 16144980 [TBL] [Abstract][Full Text] [Related]
19. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. Trippodo NC; Fox M; Monticello TM; Panchal BC; Asaad MM J Cardiovasc Pharmacol; 1999 Dec; 34(6):782-90. PubMed ID: 10598120 [TBL] [Abstract][Full Text] [Related]
20. Dual effect of angiotensin-converting enzyme inhibition on angiogenesis in type 1 diabetic mice. Ebrahimian TG; Tamarat R; Clergue M; Duriez M; Levy BI; Silvestre JS Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):65-70. PubMed ID: 15528473 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]